Novartis and its Alcon Division Report Marginally Increased Global Sales in 2014

Wednesday, February 4 2015 | 00 h 00 min | Financial News

Novartis sales increased 1%, or 3% at constant exchange rates to $ US 58 billion ($74 billion CDN). The company expects growth of approximately 5% of its net sales in 2015. Alcon, a Novartis division since 2010, reported an increase of 3% in 2014 to US $10.8 billion ($13.7 billion CDN). Sales of the Vision Care segment, which includes the launch of Dailies Total1 lenses and AirOptix Colors, increased by 2%, while sales of contact lens care products declined.

The surgery business increased by 5%, while Ophthalmic Pharmaceuticals grew by 3% due to good performance of Systane of Ilevro and treatments for glaucoma.

The Novartis report did not provide any North American or Canadian results relating to the Alcon Division.

For more information:

http://www.novartis.com/downloads/investors/financial-results/quarterly-results/q4-2014-media-release_en.pdf

EssilorLuxottica Expands Ophthalmology Footprint with Acquisition of Signifeye

EssilorLuxottica will acquire Signifeye, adding 15 Belgian clinics to its growing ophthalmology network and strengthening its integrated medical eye-care strategy.

Learn More

CORE Summarizes TFOS DEWS III Reports to Boost Dry Eye Knowledge

CORE has published issue 87 of Contact Lens Update, summarizing key findings from the TFOS DEWS III dry eye reports. Expert-authored content and downloadable PDFs provide clinicians with practical guidance on diagnosis, management, and evolving best practices.